Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

336.89 +0.61 (+0.18%)

Streaming Delayed Price Updated: 3:45 PM EST, Nov 13, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Amgen

< Previous 1 2 3 4 5 Next >

Get Ready for Next Generation of Diabetes, Weight-Management Drugs

November 01, 2023

Via Investor Brand Network

Get Ready for Next Generation of Diabetes, Weight-Management Drugs

November 01, 2023

EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END

Via FinancialNewsMedia

Investor patience tested as pharmaceutical stocks take a tumble

November 01, 2023

The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector

Via MarketBeat

Amgen Inc. (NASDAQ: AMGN) is a Leading Gainer in Tuesday Morning Trading

August 15, 2023

Via Investor Brand Network

Amgen Inc. (NASDAQ: AMGN) is a Leading Gainer in Tuesday Morning Trading

August 08, 2023

Via Investor Brand Network

Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030

October 25, 2023

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END

Via FinancialNewsMedia

Why These 3 Equal-Weighted ETFs Deserve a Portfolio Spot

October 19, 2023

These three equally-weighted exchange traded funds that offer superior diversification and risk adjusted returns are worth a look.

Via MarketBeat

Topics ETFs

Prescriptions for Portfolio Health: 3 Resilient Healthcare Stocks

October 12, 2023

During the peak of the recent selloff, the healthcare sector outshone, with three stocks showing resilience and impressive upward moves.

Via MarketBeat

Topics ETFs

Mind Science Targeting Big Brains and Portfolios

August 02, 2023

Via AB Newswire

Argenx's 28% Surge & Promising Product Propel Investor Confidence

September 25, 2023

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

Via MarketBeat

Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

September 22, 2023

FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,...

Via FinancialNewsMedia

Flee to Healthcare Stocks if Recession Rears its Head?

September 20, 2023

In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.

Via MarketBeat

Topics Economy

3 Growth Stocks to Buy in September

September 06, 2023

As the calendar turns to September, optimistic investors will look for value in quality companies with a history of generating strong revenue and earnings

Via MarketBeat

Topics Economy

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

September 01, 2023

From Horizon Therapeutics plc and Amgen

Via Business Wire

How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?

September 01, 2023

Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.

Via MarketBeat

Topics Economy

Drinks, Chips & Drugs: A Surprising List of 10-Year Stock Winners

August 11, 2023

A handful of large caps have taken things to another level. These three stocks have blown past the herd — and may be market leaders for years to come.

Via MarketBeat

Topics Bankruptcy Economy

Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions

August 08, 2023

By David Willey, Benzinga

Via TheNewswire.com

Is Growth Priced into Amgen Stock after Earnings Beat?

August 07, 2023

Amgen earnings delivered a solid earnings report after the market closed but analyst sentiment suggests that growth may already be priced into AMGN stock.

Via MarketBeat

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Amgen Inc’s Directors and Officers for Breach of Fiduciary Duties – AMGN

July 27, 2023

From Scott+Scott Attorneys at Law LLP

Via Business Wire

Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush

July 24, 2023

A bid to acquire Versanis boosts Eli Lilly & Co. by 2.80% in the past week, as the competition to develop the most effective weight-loss drug intensifies.

Via MarketBeat

Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

July 13, 2023

Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.

Via MarketBeat

Topics Retirement

Activision Surges 10% As Judge OK's Microsoft Acquisition Deal

July 12, 2023

Following a federal judge's OK of Microsoft's acquisition, Activision shares soared 10%, marking their strongest performance in over a year. The FTC can appeal.

Via MarketBeat

Activision Blizzard Shares up 1.83% Amid Regulators' Blunders

June 27, 2023

Shares of Microsoft Corp. (NASDAQ: MSFT) declined 1.92% on June 26, more than the broader market, while Activision Blizzard Inc. (NASDAQ: ATVI) rose 1.83%. The S&P 500 declined 0.41% in the session.

Via MarketBeat

Topics Stocks

Is the Biotech Industry (IBB) Poised For A Major Breakout?

June 12, 2023

The current consolidation in the IBB signals a potential breakout might be looming as key moving averages have converged within a contracted price range.

Via MarketBeat

Topics ETFs

3 Stocks Worth Buying at 52-Week Lows

May 30, 2023

Here are three stocks that are trading near their 52-week lows and may be primed for a short-term rally for opportunistic investors

Via MarketBeat

Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?

May 19, 2023

Despite worries about FTC scrutiny, Pfizer remains optimistic about its planned Seagen acquisition, issuing $31 billion in bonds to finance the deal.

Via MarketBeat

Topics Bonds

Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings

May 18, 2023

Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.

Via MarketBeat

The Turnaround for Weight Watchers is Taking Shape

May 16, 2023

Weight management meals and services provider WW International Inc. (NYSE: WW) stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares

Via MarketBeat

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amgen Inc. (AMGN)

May 11, 2023

From The Law Offices of Frank R. Cruz

Via Business Wire

AMGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Amgen Inc. and Encourages Investors to Contact the Firm

May 10, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Amgen (NQ:AMGN)

Press Releases about Amgen

Starting at $3.75/week.

Subscribe Today